Tesamorelin — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

Tesamorelin

Also known as: Egrifta, TH9507, GHRH(1-44) analog, growth hormone-releasing factor analogue, GHRH analogue

Growth hormone-releasing hormone (GHRH) analogue / synthetic growth hormone secretagogue

FDA-approvedLast updated: October 31, 2026Based on 27 peer-reviewed studies

What it is

Tesamorelin is the active ingredient in Egrifta, an FDA-approved treatment for excess belly fat in people with HIV-associated lipodystrophy. It works by stimulating the pituitary to release growth hormone, which reduces visceral fat. Prescription-only for that indication; also being studied for cognitive function and fatty liver in HIV patients.

The scientific side

Tesamorelin is a synthetic analogue of human growth hormone-releasing hormone (GHRH) that stimulates the synthesis and release of endogenous growth hormone (GH) from the pituitary gland in an episodic, pulsatile manner. By augmenting pulsatile GH secretion, tesamorelin subsequently increases insulin-like growth factor-1 (IGF-1) levels. This GH/IGF-1 axis augmentation selectively reduces visceral adipose tissue (VAT) without significantly affecting subcutaneous adipose tissue. Unlike exogenous GH administration, tesamorelin acts physiologically through the pituitary gland, restoring a more normal GH secretion profile.

Class: Growth hormone-releasing hormone (GHRH) analogue / synthetic growth hormone secretagogue

FDA-approvedHormonesDigestiveGHRH analog

At a glance

What it isA synthetic analog of growth hormone-releasing hormone (GHRH): the 44 amino acids of human GHRH plus a small fatty-acid group that makes it last longer.
Approved forReducing excess abdominal fat in adults with HIV who have lipodystrophy.
Brand namesEgrifta (2010), Egrifta SV, Egrifta WR (2025). Prescription only.
RouteInjection under the skin of the abdomen, once a day.
Label dose1.4 mg daily (Egrifta SV) or 1.28 mg daily (Egrifta WR). The original Egrifta dose was 2 mg.
Main effectAbout 15-18% less visceral (deep belly) fat after 26 weeks in the phase 3 trials. It is weight-neutral, not a weight-loss drug.
Key risksRaised blood sugar, raised IGF-1, fluid retention and joint pain, injection-site reactions.

What is Tesamorelin?

Tesamorelin is a synthetic version of growth hormone-releasing hormone (GHRH), the signal the brain uses to tell the pituitary gland to release growth hormone. The FDA label describes it as "the 44 amino acid sequence of human GRF and a hexenoyl moiety" attached at one end, a change that makes it resist breakdown.

It is made by Theratechnologies and sold in the US as Egrifta SV and Egrifta WR. Unlike most peptides on this site it went through full phase 3 trials and FDA approval. Outside that approval it is also used off-label, and like Sermorelin and CJC-1295 it is a GHRH analog.

Sources: [1] [2]

How does it work?

Tesamorelin binds GHRH receptors on the pituitary, which then releases the body's own growth hormone in pulses. Growth hormone raises IGF-1 and breaks down fat, with the strongest effect on visceral fat around the organs. Because it works through the pituitary, it needs a working hypothalamic-pituitary axis, which is why people with pituitary damage or removal cannot use it.

It is not growth hormone itself. In the trials, IGF-1 rose by about 105-122 ng/mL more than with placebo after 26 weeks.

Pharmacokinetics

Half-life8 minutes (Egrifta SV) to 11 minutes (Egrifta WR) in healthy adults
MetabolismNo formal metabolism studies in humans (label)
ClearanceNot characterized; not studied in kidney or liver impairment (label)
RouteSubcutaneous injection; absolute bioavailability under 4%; peak level about 9 minutes after the dose

Sources: [2] [3]

Is it FDA-approved?

Yes. The FDA approved tesamorelin as Egrifta on November 10, 2010. The versions sold today are Egrifta SV (named in 2019) and Egrifta WR (approved 2025).

  • Brand name: Egrifta (now Egrifta SV and Egrifta WR) (approved 2010)
  • FDA prescribing information
  • WADA: S2.2.4 Growth hormone releasing factors (named in the 2026 Prohibited List; prohibited at all times)

Sources: [4]

What is Tesamorelin prescribed for?

One use: the label says it "is indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy." Lipodystrophy here means fat building up around the organs, which can happen in people on long-term HIV treatment.

The label also sets limits: long-term heart safety "has not been established", it "is not indicated for weight loss management as it has a weight neutral effect", and prescribers should weigh stopping it in people whose visceral fat does not go down.

FDA-approved use: Reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy

Also studied for

  • Fatty liver disease (NAFLD) in people with HIV (12-month randomized trial)
  • Cognition in older adults with and without mild cognitive impairment (20-week trial)
  • Cognitive impairment in people with HIV (no significant benefit vs standard care)

Sources: [1]

Regulatory timeline

  1. November 10, 2010FDA approves Egrifta (tesamorelin), 2 mg daily, for excess abdominal fat in HIV-associated lipodystrophy. Source
  2. July 2019FDA approves the Egrifta SV name for the 2 mg/vial presentation, dosed at 1.4 mg daily. Source
  3. March 25, 2025FDA approves Egrifta WR, an 11.6 mg vial that provides seven daily 1.28 mg doses. Source

Side effects

In the 26-week placebo-controlled phase of the trials (543 people on tesamorelin, 263 on placebo), the most common side effects were joint pain, injection-site redness and itching, pain in the arms or legs, swelling, and muscle pain. Injection-site reactions overall occurred in 25% of people on tesamorelin versus 14% on placebo.

The more serious risks come from raising growth hormone and IGF-1. HbA1c rose to diabetes range (6.5% or higher) in 5% versus 1% on placebo. By week 26, 47% of people had IGF-1 above 2 standard deviations. The label calls for checking glucose before and during treatment and monitoring IGF-1.

Common

  • Injection-site reactions: 17% vs 6% on placebo
  • Joint pain (arthralgia): 13% vs 11%
  • Pain in arms or legs: 6% vs 5%
  • Muscle pain (myalgia): 6% vs 2%
  • Swelling of the legs or ankles (peripheral edema): 6% vs 2%
  • Tingling or numbness (paresthesia): 5% vs 2%

Serious

  • Glucose intolerance or diabetes: HbA1c of 6.5% or higher in 5% vs 1% on placebo
  • Elevated IGF-1: the long-term effects of prolonged elevation are unknown
  • Fluid retention, including carpal tunnel syndrome
  • Hypersensitivity reactions (rash, hives, flushing) in 4% of patients
  • Possible reactivation of a past cancer; stop if a malignancy recurs
  • Increased mortality reported with growth hormone in acute critical illness

Who should not use it

  • Disruption of the hypothalamic-pituitary axis due to hypophysectomy, hypopituitarism, pituitary tumor/surgery, head irradiation or head trauma
  • Active malignancy
  • Known hypersensitivity to tesamorelin or the excipients
  • Pregnancy

FDA label, Table 1: 26-week placebo-controlled phase of both phase 3 trials (tesamorelin N=543, placebo N=263), and Warnings and Precautions.

Sources: [2]

What does the research show?

Approval rests on two randomized, double-blind phase 3 trials in 816 adults with HIV and excess belly fat. Each had a 26-week main phase and a 26-week extension. In both, tesamorelin reduced visceral fat measured by CT scan, while fat under the skin and body weight barely changed. Triglycerides improved, and people reported less distress about their belly appearance.

The benefit did not last after stopping: people switched to placebo in the extension regained the visceral fat. Published papers report slightly different numbers from the label, because they used different analyses: 15.2% less visceral fat versus 5.0% more on placebo in the first trial, and 10.9% versus 0.6% less in the second.

Outside the approved use, a 12-month trial in people with HIV and fatty liver found a 37% relative drop in liver fat. In cognition, a 20-week trial in older adults found a benefit, but a 2025 trial in people with HIV found no significant difference from standard care.

Visceral fat change in the phase 3 trials (FDA label)

Phase and studyTesamorelinComparisonDifference (95% CI)
Study 1, weeks 0-26-18%+2% (placebo)-20% (-24 to -15)
Study 2, weeks 0-26-14%-2% (placebo)-12% (-16 to -7)
Study 1, weeks 26-520%+22% (switched to placebo)-17% (-24 to -10)
Study 2, weeks 26-52-5%+16% (switched to placebo)-18% (-24 to -11)

Mean percent change in visceral adipose tissue on CT at L4-L5, intent-to-treat, last observation carried forward. Weeks 0-26: Study 1, 273 on tesamorelin vs 137 on placebo; Study 2, 270 vs 126. Weeks 26-52 compare people who stayed on tesamorelin with people switched to placebo, measured from week 26: Study 1, 154 vs 50; Study 2, 92 vs 85.

Sources: [5] [6] [7] [8] [9] [10] [2]

FAQ

Is Tesamorelin FDA-approved?

Yes. It was approved in 2010 as Egrifta, and is sold today as Egrifta SV and Egrifta WR. The approval covers one use: excess abdominal fat in adults with HIV-associated lipodystrophy.

Sources: [4] [1]

What is Tesamorelin prescribed for?

Reducing visceral belly fat in adults with HIV who have lipodystrophy. Any other use is off-label.

Sources: [1]

Does Tesamorelin cause weight loss?

No. The label says it "has a weight neutral effect" and is not for weight loss. It reduces deep visceral fat while body weight stays about the same; lean mass rose by about 1.2-1.3 kg in the trials.

Sources: [1] [2]

Is Tesamorelin the same as growth hormone?

No. It is a GHRH analog: it signals the pituitary to release your own growth hormone, rather than replacing it. It is not a steroid.

Sources: [2]

How is Tesamorelin taken?

As a once-daily injection under the skin of the abdomen, rotating sites. Egrifta SV is mixed fresh each day; one Egrifta WR vial gives seven daily doses.

Sources: [2] [3]

What are the main side effects?

Injection-site reactions, joint and muscle pain, and swelling are the most common. The bigger risks are raised blood sugar and raised IGF-1, which is why the label asks for monitoring.

Sources: [2]

Can people without HIV use Tesamorelin?

It is only approved for adults with HIV-associated lipodystrophy. It has been studied in other groups, such as older adults in a cognition trial, but those uses are not approved.

Sources: [1] [9]

Is Tesamorelin banned in sport?

Yes. The 2026 WADA Prohibited List names tesamorelin under S2.2.4 (growth hormone releasing factors), prohibited at all times. An athlete with a medical need would have to apply for a therapeutic use exemption.

Sources: [11]

Citations

  1. EGRIFTA WR (tesamorelin) for injection, prescribing information, 2025 (BLA 022505, supplement 020). accessdata.fda.gov/drugsatfda_docs/label/2025/022505s020lbl.pdf
  2. EGRIFTA SV (tesamorelin) for injection, prescribing information, DailyMed (current label). dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224
  3. EGRIFTA WR (tesamorelin) for injection, prescribing information, DailyMed (current label). dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75
  4. Drugs@FDA: application 022505 (Egrifta), approval history. accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022505
  5. Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 2007. PMID 18057338
  6. Falutz J, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr 2010. PMID 20101189
  7. Falutz J, et al. Effects of tesamorelin (TH9507) in HIV-infected patients with excess abdominal fat: a pooled analysis of two phase 3 trials with safety extension data. J Clin Endocrinol Metab 2010. PMID 20554713
  8. Stanley TL, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV 2019. PMID 31611038
  9. Baker LD, et al. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults. Arch Neurol 2012. PMID 22869065
  10. Ellis RJ, et al. Effects of tesamorelin on neurocognitive impairment in persons with HIV and abdominal obesity. J Infect Dis 2025. PMID 39813152
  11. World Anti-Doping Agency: Prohibited List 2026, section S2.2.4 (growth hormone releasing factors). wada-ama.org/en/prohibited-list

Sources

Administration & storage

Administration
Subcutaneous injection (PMID: 31611038250383573890548839813152215160302535845025895899)
Storage
Storage conditions for tesamorelin are not stated in the reviewed abstracts.
Cautions
Injection-site reactions (erythema, localised complaints) have been reported in clinical trials of tesamorelin; these were more frequent than placebo but none judged serious in the NAFLD trial.,Growth hormone-related adverse effects including arthralgia, myalgia, paresthesia, headache, and peripheral oedema have been reported in clinical trials.,A transient early increase in fasting glucose was observed at 2 weeks in one trial (mean change +9 mg/dL vs +2 mg/dL placebo; P=0.03), though changes at 6 months were not significant. Clinicians should monitor glucose, particularly in patients with diabetes or pre-diabetes.,Discontinuation of tesamorelin results in prompt reaccumulation of visceral adipose tissue.,Long-term safety data are limited; abstracts consistently call for further research on extended treatment duration and durability of effects. Use outside approved indications (e.g., for orthopaedic or sports performance purposes) lacks safety and efficacy evidence.,Tesamorelin is prohibited by WADA; athletes should be aware of antidoping implications.,Sterile injection technique is essential when administering any subcutaneous peptide.

Legal & regulatory status

US FDA

Approved by the US Food and Drug Administration in November 2010 for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Described as the only FDA-approved therapy to treat abdominal fat…

WADA

GHRH and its synthetic analogues, including tesamorelin, are prohibited by the World Anti-Doping Agency (WADA).

Health Canada

Not stated in reviewed literature — requires manual verification